Lantern Pharma (NASDAQ:LTRN) Stock

Lantern Pharma

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Image 7

News

Pre-Market Outlook

Markets

Movers

ADPT

AGBA

BGLC

BPTH

CNTG

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HUBC

ISPC

LTRN

NFLX

PARA

RWOD

SNGX

SPCB

SPEC

TIRX

TPET

WLGS

ZCMD

Why Wang &amp; Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

Trading Ideas

AFMD

AISP

APEI

BASE

BIAF

BYSI

CERS

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

GRFS

HIPO

HSCS

IFBD

INFN

JAGX

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

SOPH

TTEC

UNFI

VINC

XRTX

Shares of  United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ALNT

AVAV

BILI

CLSK

LXEO

MBLY

PLTR

SBSW

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday

Lantern Pharma Inc

Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR&#xAE; AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%, with several recently approved ADCs achieving blockbuster status with annual sales exceeding $1 billion. Major biotech and pharmaceutical companies have recently completed ADC-focused acquisitions valued at over $10 billion, highlighting the sector's growing strategic importance. Lantern Pharma is actively advancing multiple ADC candidates through preclinical development, including a promising collaboration with the prestigious <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.uni-bielefeld.de%2Ffakultaeten%2Fchemie%2Fprojects%2Fmagicbulletreloaded%2F&amp;esheet=54191692&amp;newsitemid=20250127132783&amp;lan=en-US&amp;anchor=MAGICBULLET%3A%3AReloaded+Initiative&amp;index=1&amp;md5=9a803659c7599d166ffcca9e9afe727d">MAGICBULLET::Reloaded Initiative</a> at the University of Bielefeld in Germany.

Lantern Pharma Advances Cancer Therapies With RADR Platform and Global ADC Collaborations

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares moved upwards by 65.1% to $1.24 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock moved upwards by 32.62% to $2.48. The market value of their outstanding shares is at $3.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 32.5% to $0.11. The company's market cap stands at $1.8 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock increased by 22.48% to $12.42. The company's market cap stands at $955.7 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) stock increased by 22.19% to $42.95. The company's market cap stands at $6.7 billion. </li>
<li>Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) shares increased by 21.78% to $12.8. The company's market cap stands at $810.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock fell 23.0% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares fell 14.65% to $0.4. The company's market cap stands at $2.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock declined by 13.21% to $0.56. The company's market cap stands at $10.1 million. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) shares decreased by 11.93% to $3.25. The company's market cap stands at $35.0 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares decreased by 11.87% to $7.8. The company's market cap stands at $283.6 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares fell 9.23% to $0.14. The market value of their outstanding shares is at $11.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BDMD

BMRA

DWTX

EOLS

GCTK

HEPA

HSDT

REPL

SCPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCYC

BRNS

CADL

CVKD

ESPR

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

WIIM

Lantern Pharma shares are trading higher after the company announced it has enrolled its first patient in Taiwan for the Phase 2 HARMONIC trial of LP-300.

Biotech

General

Lantern Pharma Enrolls First Patient In Taiwan For Phase 2 HARMONIC Trial Of LP-300 Targeting Never-Smoker NSCLC Patients, Highlighting Taiwan Expansion Where Over 50% Of Lung Cancer Cases Occur In Never-Smokers, With Active Screening At Multiple Sites

Lantern Pharma shares are trading higher after the company announced LP-184 received its second fast-track designation status from the FDA for the treatment of triple-negative breast cancer.

<ul>
<li>This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.</li>
<li>Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in the US, with over 50% of patients relapsing within 3-5 years.</li>
<li>LP-184 has demonstrated significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and recent data shows promising synergy with checkpoint inhibitors in TNBC.</li>
<li>Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.</li>
<li>LP-184 is currently being evaluated in a Phase 1A clinical trial (NCT05933265) across multiple solid tumor indications, including TNBC.</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for Glioblastoma in October.

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation From FDA For Treatment Of Triple Negative Breast Cancer

Lantern Pharma & Starlight Therapeutics Announce Presentation Of LP-184  Phase 1b Trial Design And Preclinical Data In Glioblastoma At Society for Neuro-Oncology 2024

<ul>
<li>Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months</li>
<li>U.S. clinical sites continue to actively screen and dose patients in both the LP-300 combination arm and the standard-of-care control arm of the Harmonic trial
<ul>
<li>Non-small cell lung cancer (NSCLC) in never smokers occurs at rates 2 to 3 times higher in East Asian countries versus the US and Europe.</li>
</ul>
</li>
</ul>

Lantern Pharma Doses First Patient In Japan For Expansion Cohort In Phase 2 HARMONIC Clinical Trial Of LP-300 In Never-Smoker NSCLC Patients

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.56) by 25 percent.

Earnings

Earnings Beats

Lantern Pharma Q3 2024 GAAP EPS $(0.42) Beats $(0.56) Estimate

Lantern Pharma shares are trading higher after the company announced LP-184 received FDA fast-track designation status for Glioblastoma.

Lantern Pharma's LP-184 Receives FDA Fast-Track Designation In Glioblastoma

Lantern Pharma Receives Three FDA Rare Pediatric Disease Designations For LP-184 In Malignant Rhabdoid Tumors, Rhabdomyosarcoma, And Hepatoblastoma, Bringing Total To Four RPDDs

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf</a>

Analyst Ratings

Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

Lantern Pharma shares are trading lower. The company reported Q2 financial results.

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 4.55 percent decrease over losses of $(0.44) per share from the same period last year.

Lantern Pharma Q2 2024 GAAP EPS $(0.46) Beats $(0.55) Estimate

Lantern Pharma Announces Significant Advancement In Preclinical Synergy Of LP-184 With Checkpoint Inhibitors; To Present Data At Immuno-Oncology Summit 2024

<ul>
<li>The Phase 2 HARMONIC&#x2122; study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common in never smokers – that lead to tyrosine kinase inhibitor (TKI) treatment resistance, and to enhance patient outcomes when LP-300 is used with the standard-of-care chemotherapy doublet.</li>
<li>In the Phase 2 lead-in cohort of 7 patients, 6 patients experienced clinical benefit from the combination of LP-300 and chemotherapy while 1 patient experienced progressive disease.</li>
<li>Of the 6 patients experiencing clinical benefit – 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%.</li>
<li>The clinical benefit rate and disease control rate is 86% for this group with an objective response rate (ORR) of 43%.</li>
<li>A preliminary analysis of data in the safety lead-in part of the trial indicates no additional safety concerns with no observed dose limiting toxicities (DLTs) and no reported treatment-related serious adverse events (SAEs).</li>
<li>Encouraging preliminary efficacy results were observed regardless of prior tyrosine kinase inhibitor (TKI) treatment(s), demographics, and metastatic disease sites.</li>
<li>In the initial set of patients, those having low to intermediate TMB (tumor mutation burden) were found to be responsive to LP-300 + chemotherapy.</li>
<li>There are no currently approved therapies or targeted agents specifically approved for use in NSCLC among never-smokers, which is a growing global class of patients.</li>
</ul>
Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced positive, preliminary results from the initial patient group in the ongoing HARMONIC&#x2122; phase 2 clinical trial. HARMONIC&#x2122; is evaluating Lantern Pharma's investigational new drug candidate, LP-300, in combination with pemetrexed and carboplatin in never smokers1 with advanced non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with a tyrosine kinase inhibitor (TKI). LP-300 was advanced in part with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lanternpharma.com%2Fai-platform&amp;esheet=54104073&amp;newsitemid=20240805396240&amp;lan=en-US&amp;anchor=Lantern%26%238217%3Bs+AI+platform%2C+RADR%26%23174%3B&amp;index=1&amp;md5=32bb134540850a577eaa35f44e4c1a77">Lantern's AI platform, RADR&#xAE;</a>, to aid in the validation of mechanisms and uncover insights in targeted patient populations. RADR&#xAE; is Lantern's AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern's portfolio and development initiatives with Lantern's collaborators.

Lantern Pharma Shares Clinical Update From Ongoing Phase 2 HARMONIC Clinical Trial For Never Smokers With Advanced NSCLC, Including An 86% Clinical Benefit Rate In The Initial Patient Cohort

Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The diagnostic is currently based on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FReal-time_polymerase_chain_reaction&amp;esheet=54092753&amp;newsitemid=20240710249401&amp;lan=en-US&amp;anchor=qRT-PCR&amp;index=1&amp;md5=9a1c9951081542f28089f718b6c729f7">qRT-PCR</a> (quantitative real-time polymerase chain reaction) technology and is focused on quantifying the amount of PTGR1 RNA in patient tumor samples to assess the potential for sensitivity to Lantern's drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184.

Lantern Pharma Achieves Milestone Towards Development Of Molecular Diagnostic For Use In Oncology Clinical Trials For Patient Selection And Stratification With Drug Candidate LP-184;  Confirmed PTGR1 As A Key Biomarker That It Intends To Use To Optimize Patient Selection Based On Potential Tumor Sensitivity To The Drug Candidate LP-184

Lantern Estimates That LP-284 Can Have The Potential To Improve Outcomes For 40,000 To 80,000 Patients With Blood Cancers Annually, With A Global Annual Market Potential Of $4B

Press Releases

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Comments

Lantern Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga